Daiichi Sankyo net profit dips by 78% in first nine months - pharmabiz.com
Daiichi Sankyo net profit dips by 78% in first nine monthspharmabiz.
Forest Laboratories, Inc. Reports Fiscal Year Third Quarter 2012 Earnings Per ... - MarketWatch (press release)
Forest Laboratories, Inc.
Congress MP terms proposed pharma policy incomplete and disappointing - pharmabiz.com
Congress MP terms proposed pharma policy incomplete and disappointingpharmabiz.
Takeda gains approval for hypertension drug Azilva in Japan - PMLiVE
Takeda gains approval for hypertension drug Azilva in JapanPMLiVEPrior studies had also shown it to be superior to valsartan, developed and sold by Novartis as Diovan, and Daiichi Sankyo's Benicar/Olmetec (olmesartan).
Forest Labs EPS beat consensus forecasts - The Pharma Letter
Forest Labs EPS beat consensus forecastsThe Pharma LetterBenicar (olmesartan medoxomil) co-promotion income decreased to $31.